Navigation Links
Can EP4 agonist alleviate gastric lesions?
Date:11/18/2009

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding. To mitigate NSAIDs' adverse effects on the stomach, misoprostol, a non-selective prostaglandin E1 (PGE1) analogue, has been prescribed as the first choice for prevention of NSAID-induced injuries, but often induces severe adverse effects. There remain unmet medical needs for drugs with improved therapeutic profiles.

A research article published on November 7, 2009 in the World Journal of Gastroenterology addresses this question. A research team from United States investigated therapeutic potentials of a highly-selective EP4 agonist for treatment of a mouse gastric ulcer model in the presence or absence of indomethacin at various levels.

They found the EP4-selective agonist reduced high dose indomethacin-induced acute hemorrhagic damage and promoted mucous epithelial regeneration. Low-dose indomethacin aggravated ulcer bleeding and inflammation, and delayed the healing of the established chronic gastric ulcer. The EP4 agonist, when applied locally, not only offset indomethacin-induced gastric bleeding and inflammation, but also accelerated ulcer healing. In the absence of indomethacin, the EP4 agonist even accelerated chronic gastric ulcer healing and suppressed inflammatory cell infiltration in the granulation tissue. In vitro, the EP4 agonist protected human gastric mucous cells from indomethacin-induced apoptosis.

Their results suggest that EP4 agonists may mimic the gastric protective effects of PGE2 in the presence or absence of NSAIDs, and may show advantages over non-selective analogs such as misoprostol by minimizing adverse effects arising from activating all 4 subtype receptors of PGE2.


'/>"/>

Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. How IAP antagonist chemicals kill tumors
2. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
3. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity
6. TorreyPines NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
7. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
8. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
9. Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
10. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
11. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ( WEDI ... efficiencies in healthcare information exchange, announced the release of its findings from its June ... (HHS) Secretary, WEDI shared survey results and recommendations , strongly encouraging ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bodybuilding.com, ... of nutritional supplements, has officially opened the polls for their eleventh annual ... following categories:, ,     Brand of the Year (BPI Sports) ...
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing ... from her grandmother’s side at a young age, Nasreen Zereshki was extremely eager to ... to share her cookbook Recipes from My Persian Kitchen with the world. , Since ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2
... South Korea, July 20 HepaHope Korea ... owned subsidiary, VASKA, a Berkeley-based producer of green, botanically-based ... successfully turned the first major commercial laundry plant in the United ... South San Francisco is the largest privately owned commercial laundry on ...
... , CARY, N.C., July 20 ... company focused on acquiring, developing and commercializing products primarily for ... Executive Vice President, Finance, and Chief Financial Officer, has been ... in the Small Public Business category. Award recipients were ...
... CARLSBAD, Calif., July 20 SynergEyes, Inc., ... a new advanced lens design for keratoconus patients. ClearKone(TM) ... the best features of the hybrid platform, providing superior ... design is optimized to vault the predominant irregularities of ...
... , BANNOCKBURN, Ill., July 20 Heart disease is ... it,s often not until the untimely passing of a celebrity from a ... the issue is brought to the forefront of Americans, health and wellness ... a recent survey(2) uncovered that only 14 percent of people would be ...
... Population older than 65 could reach 1.3 billion by 2040 ... people who are age 65 and older will double from ... 2040, says a new U.S. Census Bureau study. , The ... last year to 1.3 billion in 30 years. The unprecedented ...
... PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 The ... partnership to accelerate LLS,s pipeline of research projects entering late pre-clinical ... will begin with a selection of ten small molecule candidates, discovered ... of advancing into clinical trials in the shortest period of time. ...
Cached Medicine News:Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Cornerstone Therapeutics' David Price Named 2009 Chief Financial Officer of the Year by the Triangle Business Journal 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 3Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 3Health News:Elder Boom Will Be Felt Worldwide 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 3
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... Pa., Dec. 7, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... to fight cancers and infectious diseases, announced today that ... shares of its common stock and warrants to purchase ... which included the partial exercise of the underwriter,s overallotment ...
... -- The November 14, 2011, edition of ... Presence (VIP) as 4 stars ("would take it on ... Experiment (AEWE),s Spiral G at Fort Benning, GA, culminating ... and November 2011.  "It was a pleasure ...
Cached Medicine Technology:Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 2Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 3Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 4VIPAAR's VIP Earns 4-star Technology Rating at AEWE's Spiral G 2
... Oxyflo is a highly featured laser ... microvascular blood perfusion from multiple tissue ... developments in Digital Signal Processing (DSP) ... technologically advanced, yet simple to use, ...
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Imexlab 3000DX bidirectional vascular testing system ... for the physician concerned with arterial ... designed and made by Nicolet Vascular, ... diagnostic systems chosen by thousands of ...
Medicine Products: